Affimed Therapeutics (GER)

Affimed is a clinical stage company developing bispecific RECRUIT-TandAb® antibodies in oncology. The lead product AFM13 is currently investigated in PhaseI/IIa trials in Hodgkin's lymphoma patients. The product appears to be safe and well tolerated and showed initial efficacy in patients. A second program, AFM11, is developed for the treatment of NHL. TandAbs® possess increased therapeutic potential compared to monoclonal antibodies or other antibody fragments. They have drug-like properties with excellent product stability. A robust manufacturing process has been established. Affimed is backed by a peer group of investors including Orbimed, Aeris, LSP, BioMed Invest and Novo Nordisk A/S.